Article Information
History
- April 5, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Franck Touret1,*,
- Magali Gilles1,
- Karine Barral2,
- Antoine Nougairède1,
- Etienne Decroly3,
- Xavier de Lamballerie1 and
- Bruno Coutard1,*
- 1Unité des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), 13005 Marseille, France
- 2Aix-Marseille Univ, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, CRCM, Marseille, France
- 3Aix Marseille Université, CNRS, AFMB UMR 7257, Marseille, France
- ↵*Corresponding authors: franck.touret{at}univ-amu.fr; bruno.coutard{at}univ-amu.fr
Posted April 05, 2020.
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
